-
Advancing MIBC Treatment: ADCs, AI Models & Bladder-Sparing Strategies
At #EAU25, we spoke with Prof. Haibin Chen and Prof. Ruiyi Zhang from Renji Hospital, Shanghai Jiao Tong University, who shared updates on their team’s research in muscle-invasive bladder cancer (MIBC). They discussed a new study exploring ADC therapy for HER2+ MIBC, as well as progress in bladder-sparing treatment, ctDNA-based monitoring, and AI-driven molecular profiling…
-
Biopsy-Free Strategy in Prostate Cancer: Prof. Shousheng Chen at EAU25
At hashtag#EAU25, Prof. Shousheng Chen (陈守臻) from Qilu Hospital of Shandong University shared key findings from his study on a “biopsy-free” diagnostic approach for prostate cancer using PSMA PET/CT, mpMRI, and serum biomarkers. He discussed how this strategy compares with traditional PSA and DRE, its potential in early diagnosis, and how it could guide follow-up…
-
Bladder-Sparing vs. Radical Cystectomy – Prof. Liangyou Gu Shares Insights at EAU25
At hashtag#EAU25 in Madrid, we had the opportunity to interview Professor Liangyou Gu from the General Hospital of the Chinese PLA, who shared his clinical perspective on emerging treatment strategies for muscle-invasive bladder cancer (MIBC). With ongoing breakthroughs in MIBC research, bladder-sparing approaches are gaining traction alongside radical cystectomy. Prof. Gu offered his insights on…
-
EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC
At the 2025 EAU Congress, Prof. Junlong Zhuang (Nanjing Drum Tower Hospital) and Prof. Samson Chan (Department of Surgery, Tuen Mun Hospital, Hong Kong) sat down with Urology Frontier to discuss new insights from the Phase II PROact study. The study evaluated a triple combination of olaparib + abiraterone + prednisone in metastatic hormone-sensitive prostate…
-
ELCC 2025 | Dr. Antonio Passaro Discusses TKI Combination Therapy as Standard First-Line Treatment for EGFR-Mutant NSCLC
At the 2025 European Lung Cancer Conference (ELCC), Professor Antonio Passaro from the European Institute of Oncology (IEO), Italy, led a deep discussion during the controversy session on the topic, “Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?”
-
EAU 2025 | Exploring Non-invasive Diagnosis and Combination Therapy for Renal Cancer — Professor Xiongjun Ye’s Team Advances Clinical Practice
1. UroStream: MRI has rapidly developed, but challenges remain in accurately identifying renal tumors. What advancements has your team made in this area? Professor Xiongjun Ye: Currently, the diagnosis of…
-
SGBCC 2025丨Professor Cicero Urban: New Perspectives—Redefining the Patient Population for Axillary Surgery in Early Breast Cancer
Oncology frontier: The current applicability of axillary surgery (such as SLNB or ALND) in early-stage breast cancer is a subject of controversy. In your report at SGBCC, you mentioned that…
-
SGBCC 2025 | Professor Cuizhi Geng: Multiple Posters Presented, China’s Innovations Take the Global Stage
Oncology Frontier: Your hospital presented multiple posters at this year’s SGBCC. Could you share some of the most notable advances? How will these posters contribute to the global development of…
Connecting Medical Expertise through Media